Rallybio Corporation (RLYB)
Rallybio Corporation at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Rallybio Corporation (RLYB) is a Biotechnology company based in US with a market capitalization of $76.3M. Free cash flow was negative at -$29.8M. This page tracks RLYB's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 15 employees · IPO Jul 29, 2021
Valuation
Valuation & price
$14.30as of May 17, 2026· -15.2% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
1.32
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$76.3M
Market cap
—
Revenue growth (YoY)
89.3%
Gross margin
-$29.8M
Free cash flow (USD)
-$54.6M
Net debt
Net cash position
3.4%
Share dilution
2/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2019 → 2025
Free cash flow by year
2019 → 2025
Gross margin by year
2024 → 2025
Value screen
Graham defensive-investor tests
4
Insider buys · 90 days
0
Insider sells · 90 days
Earnings
Last report: 10-Q filed May 13, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
- 8-K eventJun 1, 2026Filing
Merger Agreement
- Insider buyMay 20, 2026Filing
Insider Buy $227KADAR1 Capital Management, LLC · 10% Owner · $226.6K
- Insider buyMay 15, 2026Filing
Insider Buy $1.1MADAR1 Capital Management, LLC · 10% Owner · $1.1M
- Insider buyMay 13, 2026Filing
Insider Buy $711KADAR1 Capital Management, LLC · 10% Owner · $711.1K
- Quarterly reportMay 13, 2026Filing
10-Q Filed
- Insider buyMay 6, 2026Filing
Insider Buy $2.2MADAR1 Capital Management, LLC · 10% Owner · $2.2M
- 8-K eventMay 4, 2026Filing
Merger Agreement Termination
- 8-K eventMar 31, 2026Filing
CMO Departure
Questions
Frequently asked questions
What is Rallybio Corporation's market cap?
Rallybio Corporation (RLYB) has a market capitalization of $76.3M.
What is RLYB's P/E ratio?
A meaningful P/E ratio is not available for RLYB — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
What is RLYB's price-to-book (P/B) ratio?
RLYB trades at 1.32 times book value per share.
Are insiders buying RLYB stock?
Yes — SEC Form 4 filings show 4 open-market insider buys and 0 sells at Rallybio Corporation in the last 90 days.
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.